Technical Analysis for CARA - Cara Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.26 | 1.94% | 0.01 |
CARA closed up 1.94 percent on Monday, July 1, 2024, on 1.22 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Volume Surge | Other | 1.94% | |
| Wide Bands | Range Expansion | 1.94% | |
| Gapped Down | Weakness | 1.94% | |
| Oversold Stochastic | Weakness | 1.94% | |
| Wide Bands | Range Expansion | -13.63% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 4 hours ago |
| 10 DMA Resistance | about 4 hours ago |
| Possible NR7 | about 6 hours ago |
| Possible Inside Day | about 6 hours ago |
| 60 Minute Opening Range Breakdown | about 9 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/05/2024
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat pain. Its products include intravenous CR845 that has completed Phase II clinical trials for the treatment of acute postoperative pain in adult patients; Oral CR845, which is in Phase I clinical trials to treat acute and chronic pain; and CR701 that is in preclinical trials for treating neuropathic and inflammatory pain. The company was founded in 2004 and is based in Shelton, Connecticut.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pain Clinical Trial Chronic Pain Amines Acute And Chronic Pain Piperidines Mesoblast
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pain Clinical Trial Chronic Pain Amines Acute And Chronic Pain Piperidines Mesoblast
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.45 |
| 52 Week Low | 0.24 |
| Average Volume | 769,629 |
| 200-Day Moving Average | 0.90 |
| 50-Day Moving Average | 0.61 |
| 20-Day Moving Average | 0.45 |
| 10-Day Moving Average | 0.28 |
| Average True Range | 0.07 |
| RSI (14) | 30.56 |
| ADX | 26.99 |
| +DI | 15.75 |
| -DI | 30.00 |
| Chandelier Exit (Long, 3 ATRs) | 0.52 |
| Chandelier Exit (Short, 3 ATRs) | 0.45 |
| Upper Bollinger Bands | 0.82 |
| Lower Bollinger Band | 0.08 |
| Percent B (%b) | 0.25 |
| BandWidth | 165.43 |
| MACD Line | -0.11 |
| MACD Signal Line | -0.10 |
| MACD Histogram | -0.0084 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.30 | ||||
| Resistance 3 (R3) | 0.30 | 0.29 | 0.29 | ||
| Resistance 2 (R2) | 0.29 | 0.28 | 0.29 | 0.29 | |
| Resistance 1 (R1) | 0.28 | 0.28 | 0.27 | 0.27 | 0.29 |
| Pivot Point | 0.27 | 0.27 | 0.27 | 0.27 | 0.27 |
| Support 1 (S1) | 0.25 | 0.26 | 0.25 | 0.25 | 0.24 |
| Support 2 (S2) | 0.25 | 0.26 | 0.24 | 0.24 | |
| Support 3 (S3) | 0.23 | 0.25 | 0.23 | ||
| Support 4 (S4) | 0.23 |
